JP2018535963A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535963A5 JP2018535963A5 JP2018521608A JP2018521608A JP2018535963A5 JP 2018535963 A5 JP2018535963 A5 JP 2018535963A5 JP 2018521608 A JP2018521608 A JP 2018521608A JP 2018521608 A JP2018521608 A JP 2018521608A JP 2018535963 A5 JP2018535963 A5 JP 2018535963A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- alkyl
- salt
- atom
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 1
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000008728 vascular permeability Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15191759.8 | 2015-10-27 | ||
| EP15191759 | 2015-10-27 | ||
| PCT/EP2016/075222 WO2017072021A1 (en) | 2015-10-27 | 2016-10-20 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535963A JP2018535963A (ja) | 2018-12-06 |
| JP2018535963A5 true JP2018535963A5 (enExample) | 2019-12-05 |
| JP6855477B2 JP6855477B2 (ja) | 2021-04-07 |
Family
ID=54360328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521608A Active JP6855477B2 (ja) | 2015-10-27 | 2016-10-20 | 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10640486B2 (enExample) |
| EP (1) | EP3368524B1 (enExample) |
| JP (1) | JP6855477B2 (enExample) |
| WO (1) | WO2017072021A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| US10640486B2 (en) | 2015-10-27 | 2020-05-05 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| RU2739447C2 (ru) | 2016-05-31 | 2020-12-24 | Калвиста Фармасьютикалз Лимитед | Производные пиразола в качестве ингибиторов калликреина |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| JP7175914B2 (ja) * | 2017-04-21 | 2022-11-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害剤としてのヘテロアリールカルボキサミド誘導体 |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| IL274557B2 (en) | 2017-11-29 | 2024-09-01 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibitor |
| JP6828191B2 (ja) | 2018-08-16 | 2021-02-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害剤としての複素芳香族カルボキサミド誘導体 |
| CN112839711A (zh) | 2018-10-10 | 2021-05-25 | 勃林格殷格翰国际有限公司 | 作为血浆激肽释放酶抑制剂的苯基四唑衍生物 |
| CN109232416B (zh) * | 2018-10-24 | 2021-09-24 | 福州大学 | 一种合成4-三氟甲基-2-吡喃酮/吡啶酮化合物的方法 |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| CN113004286B (zh) * | 2019-12-20 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为血浆激肽释放酶抑制剂的三环类化合物及其用途 |
| CN113004284B (zh) * | 2019-12-20 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为血浆激肽释放酶抑制剂的四环类化合物及其用途 |
| CN113004283B (zh) * | 2019-12-20 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为血浆激肽释放酶抑制剂的四环类化合物及其用途 |
| TW202535863A (zh) * | 2020-02-13 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| TW202144331A (zh) * | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
| BR112022025528A2 (pt) | 2020-06-16 | 2023-01-17 | Merck Sharp & Dohme Llc | Composto, composição farmacêutica, e, métodos para tratar atividade visual prejudicada, retinopatia diabética, edema macular diabético, oclusão de veia retinal, angioedema hereditário, diabete, pancreatite, hemorragia cerebral, nefropatia, cardiomiopatia, neuropatia, doença intestinal inflamatória, artrite, inflamação, choque séptico, hipotensão, câncer, síndrome da angústia respiratória do adulto, coagulação intravascular disseminada, coagulação sanguínea durante cirurgia de desvio cardiopulmonar ou hemorragia do pós-operatório de cirurgia e para tratar uveíte, uveíte posterior, edema macular relacionado com a idade úmido |
| MX2023000507A (es) * | 2020-07-10 | 2023-02-09 | Merck Sharp & Dohme Llc | Inhibidores de la calicreina plasmatica. |
| WO2023144030A1 (en) | 2022-01-31 | 2023-08-03 | Oxurion NV | Plasma kallikrein inhibitor therapy for anti-vegf sensitization |
| WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| US20050090529A1 (en) * | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US8658685B2 (en) * | 2008-01-31 | 2014-02-25 | Activesite Pharmaceuticals, Inc. | Methods for treatment of kallikrein-related disorders |
| US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| EP2807156A1 (en) * | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| US20140378474A1 (en) * | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| RU2712621C2 (ru) * | 2013-05-23 | 2020-01-30 | Калвиста Фармасьютикалз Лимитед | Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы |
| JP6917988B2 (ja) | 2015-10-27 | 2021-08-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体 |
| US10640486B2 (en) | 2015-10-27 | 2020-05-05 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
-
2016
- 2016-10-20 US US15/770,763 patent/US10640486B2/en active Active
- 2016-10-20 EP EP16784892.8A patent/EP3368524B1/en active Active
- 2016-10-20 WO PCT/EP2016/075222 patent/WO2017072021A1/en not_active Ceased
- 2016-10-20 JP JP2018521608A patent/JP6855477B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535963A5 (enExample) | ||
| JP2018536648A5 (enExample) | ||
| JP2020506178A5 (enExample) | ||
| JP2016517417A5 (enExample) | ||
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| JP2017507160A5 (enExample) | ||
| JP2017518959A5 (enExample) | ||
| JP2018526367A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| JP2016508506A5 (enExample) | ||
| JP2018515495A5 (enExample) | ||
| JP2016513130A5 (enExample) | ||
| JP2016530262A5 (enExample) | ||
| JP2012507566A5 (enExample) | ||
| JP2012530703A5 (enExample) | ||
| JP2019522055A5 (enExample) | ||
| JP2016500661A5 (enExample) | ||
| RU2019100164A (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| JP2013500314A5 (enExample) | ||
| EA031655B1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| JP2020517619A5 (enExample) | ||
| JP2014514290A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| JP2020520957A5 (enExample) | ||
| JP2019519616A5 (enExample) |